ORGO

Over the past six months, Organogenesis Holdings, Inc. (ORGO) stock declined approximately 45.8%, trading between $1.25 and $7.08 over the past 52 weeks. Key events included a significant Q2 2026 earnings miss in August 2026, where the company reported an adjusted loss and missed revenue estimates, leading to a 22.8% stock drop due to a 58% year-over-year revenue plunge attributed to CMS coverage changes and a cut in 2026 revenue guidance. The company also restructured operations, reducing its direct sales force to adapt to new Medicare reimbursement rules and cut costs. Organogenesis launched an at-the-market equity program for up to $75 million. Positive developments included the FDA's acceptance of its Biologics License Application (BLA) for ReNu in June 2026, targeting symptomatic knee osteoarthritis, and the publication of positive clinical trial results for Affinity in complex venous leg ulcers in July 2026.